🇺🇸 FDA

Intelligence Platform

Patents

Browse 88 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12421316

Bispecific immunotoxins targeting human CD25+CCR4+ tumors and regulatory T-cells

The Regents of the University of Colorado, a Body Corporate · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12421287

T-cell modulatory multimeric polypeptides and methods of use thereof

Cue Biopharma, Inc. · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12304942

Cell comprising a chimeric antigen receptor or a transgenic T-cell receptor and comprising

AUTOLUS LIMITED · Granted Tue May 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 15 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12304968

T-cells expressing anti-LIV1 chimeric antigen receptor

CRISPR THERAPEUTICS AG · Granted Tue May 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 15 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12297452

Methods or generating T-cells from stem cells and immunotherapeutic methods using the T-ce

The Regents of the University of California · Granted Tue May 13 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12257311

Multimeric T-cell modulatory polypeptides and methods of use thereof

Cue Biopharma, Inc. · Granted Tue Mar 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12215162

BAFF-R targeted chimeric antigen receptor-modified T-cells and uses thereof

The Board of Regents of the University of Texas System · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12195724

Methods of producing T cell populations enriched for stable regulatory T-cells

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jan 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12187780

Car t-cells comprising inactivated CBL and CBL-B genes

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12180258

T-cell modulatory multimeric polypeptides and methods of use thereof

Cue Biopharma, Inc. · Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12152061

T-cell modulatory multimeric polypeptides and methods of use thereof

Cue Biopharma, Inc. · Granted Tue Nov 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12145973

T-cell modulatory multimeric polypeptides and methods of use thereof

Cue Biopharma, Inc. · Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12139522

T-cells comprising two different chimeric antigen receptors and uses thereof

THE MEDICAL RESEARCH INFRASTRUCTURE AND HEAL SERVICED FUND OF THE TEL AVIV MEDECAL CENTER · Granted Tue Nov 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12104172

Processes for generating TIL products enriched for tumor antigen-specific t-cells

Iovance Biotherapeutics, Inc. · Granted Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12053513

Cancer-specific T-cell receptors

University College Cardiff Consultants Limited · Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12049487

Universal chimeric antigen receptor T-cell preparation technique

GRACELL BIOTECHNOLOGIES (SHANGHAI) CO., LTD. · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12029782

MHC class II T-cell modulatory multimeric polypeptides for treating type 1 diabetes mellit

Cue Biopharma, Inc. · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12006348

T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof

Cue Biopharma, Inc. · Granted Tue Jun 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11987610

T-cell modulatory multimeric polypeptides and methods of use thereof

Cue Biopharma, Inc. · Granted Tue May 21 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 16 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11944644

T-cells comprising anti-CD38 and anti-CD138 chimeric antigen receptors and uses thereof

The Medical Research, Infrastructure and Health Services Fund of the Tel-Aviv Medical Center · Granted Tue Apr 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11905320

T-cell modulatory multimeric polypeptides and methods of use thereof

Cue Biopharma, Inc. · Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11897874

Compounds and methods for modulating Interleukin-2-inducible T-cell kinase

Corvus Pharmaceuticals, Inc. · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11885807

Method for depleting malignant T-cells

AUTOLUS LIMITED · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11885806

Method for depleting malignant T-cells

AUTOLUS LIMITED · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted